Abstract
•Cit-UCNPs can serve as effective multimodal imaging agents.•Cit-UCNPs demonstrate excellent biological safety.•Improved imaging and biocompatibility can significantly enhance clinical care.
There has been significant progress with rare-earth coated upconversion nanoparticles (UCNPs) representing a promising new generation of contrast agents for biomedical applications. However, in vivo biological safety remains poorly investigated. This work examined citric acid-UCNP (NaYF4:Yb3+/Gd3+, ∼ 5 nm, Cit-UCNP) generated as contrast agents for multimodal imaging with concurrent magnetic resonance (MRI) and X-ray computed tomography (CT). We first examined the in vitro cytotoxicity and efficacy of Cit-UCNPs as a contrast agent. We then performed a systematic investigation of their in vivo biodistribution and biocompatibility. Our results noted that Cit-UCNPs have minimal toxicity and demonstrated significant potential as contrast agents for multimodal biomedical imaging. This study indicates Cit-UCNPs could be a valuable addition to enhance long-term targeted diagnostic and prognostic multimodal clinical imaging approaches.